Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year High – What’s Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR) hit a new 52-week high on Thursday . The company traded as high as $120.42 and last traded at $119.8760, with a volume of 5572 shares changing hands. The stock had previously closed at $119.23.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MNPR. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. BTIG Research upped their price objective on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $112.08.

Monopar Therapeutics Trading Up 4.1%

The stock has a market capitalization of $831.08 million, a P/E ratio of -64.79 and a beta of 1.47. The company has a 50-day moving average price of $88.63 and a 200 day moving average price of $69.35.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. As a group, research analysts expect that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in Monopar Therapeutics in the first quarter valued at approximately $673,000. Jane Street Group LLC acquired a new position in shares of Monopar Therapeutics during the first quarter worth $377,000. Geode Capital Management LLC increased its position in shares of Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after purchasing an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $209,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.